Syntis Bio
Syntis Bio Raises $33M in Series A
Syntis Bio Raises $33M in Series A
Syntis Bio has successfully raised $33M in a Series A led by Cerberus Ventures.
Company Overview
Syntis Bio is a HealthTech company headquartered in Cambridge, MA, founded in 2022 with 50+ employees.
Developing oral therapies for obesity diabetes and rare diseases
Fundraising Details
- Amount Raised: $33M
- Round Type: Series A
- Date: 2025-06-14
- Investors: Cerberus Ventures
About Syntis Bio
Developing oral therapies for obesity diabetes and rare diseases The company is positioned in the HealthTech sector, serving a growing market with innovative solutions.
Key Information
- Headquarters: Cambridge, MA
- Founded: 2022
- Team Size: 50+
- Industry: HealthTech
What This Means
This funding round demonstrates strong investor confidence in Syntis Bio's vision and execution. The capital will likely be used to:
- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities
Industry Context
The HealthTech sector continues to attract significant investment as companies innovate to meet evolving market demands. Syntis Bio's successful fundraising reflects the strong fundamentals and growth potential in this space.
Looking Ahead
With this new capital, Syntis Bio is well-positioned to execute on its growth strategy and continue building innovative solutions in the HealthTech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.
This fundraising news was reported on 2025-06-14. For more information about Syntis Bio, visit their headquarters at Cambridge, MA.
Company Info
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started